Nemvaleukin Fails to Show OS Benefit Over Chemotherapy in Platinum-Resistant Ovarian Cancer
8 Articles
8 Articles
Questions and Answers About Recurrent Ovarian Cancer
An ovarian cancer recurrence means the disease has returned after you’ve gone into remission or been declared disease-free. While survival rates for people with recurrent ovarian cancer are currently around 3 in 10, knowing your risks, advocating for yourself, and actively participating in your treatment and care can improve your outcome and your outlook. We spoke with Blair McNamara, M.D., a gynecologic oncologist at Yale University School of M…
Clinically Speaking: Questions and Answers About Recurrent Ovarian Cancer
An ovarian cancer recurrence means the disease has returned after you’ve gone into remission or been declared disease-free. While survival rates for people with recurrent ovarian cancer are currently around 3 in 10, knowing your risks, advocating for yourself, and actively participating in your treatment and care can improve your outcome and your outlook. We spoke with Blair McNamara, M.D., a gynecologic oncologist at Yale University School of M…
Nemvaleukin combo fails in Phase 3 trial in resistant ovarian cancer
Interim data from a Phase 3 trial failed to show that a combination of nemvaleukin, an experimental immune-modulating therapy, and Keytruda (pembrolizumab) could outperform standard chemotherapy in extending survival with platinum-resistant ovarian cancer. Based on the lackluster findings, nemvaleukin’s developer Mural Oncology is ending the clinical trial early and stopping work on nemvaleukin in platinum-resistant ovarian cancer. “We are disap…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium